news
New organoid model helps test spinal cord regeneration drugs
Northwestern scientists have grown human spinal cord organoids to test therapies that could reduce scarring and promote nerve regrowth in patients.
List view / Grid view
Screening
news
New OC-PAM AI tool tracks cancer organoid drug response
Scientists have developed an AI-enhanced imaging platform that enables non-invasive, label-free and longitudinal monitoring of cancer organoids and spheroids.
news
New SerpinB2 immune cell discovery could reverse type 2 diabetes
Researchers at the University of Pittsburgh School of Medicine have developed a new approach for tackling insulin resistance and type 2 diabetes by protecting beneficial immune cells in fat tissue.
news
New SHANK3 conditional knockout mouse model launched for PMS research
A new SHANK3 conditional knockout mouse model from InnoSer, CureSHANK and Ozgene has been launched to advance research into Phelan-McDermid syndrome, other neurodevelopmental disorders and the development of new therapies.
article
Quantum chemistry reveals a new route to selective JAK2 inhibition
Mutant selectivity remains one of drug discovery’s hardest problems. New preclinical research applying quantum chemistry to JAK2V617F illustrates how detailed molecular analysis can inform more selective inhibitor design.
news
Charles River and Synthace announce partnership for assay development
Announced at SLAS 2026 in Boston, Synthace have partnered with Charles River Laboratories to advance assay development, combining software, automation and experimental design.
article
AI in drug discovery: 2025 in review
For those that hoped artificial intelligence would help to deliver drugs that actually work, the hope lives on. Here, Dr Raminderpal Singh reflects on the sobering reality check that 2025 delivered to the industry.
article
Beyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
news
New lab-made antibody targets drug-resistant bacteria
Scientists have developed a lab-made antibody that targets a sugar found only on bacterial cells, successfully clearing deadly, drug-resistant infections in mice.
whitepaper
CRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
news
CC023 mice reveal how ALS can develop after viral infections
Researchers have discovered a mouse strain that mirrors ALS in humans following a viral infection, offering new insights into how the disease develops, potentially opening new pathways for early diagnosis and drug development.
news
Targeting cPLA2 enzyme may reduce brain inflammation in Alzheimer’s
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
article
Drug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
article
Targeting inflammatory cell death to tackle relapse in AML
Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.
article
Disrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
